197 related articles for article (PubMed ID: 19742320)
1. A new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosis.
Patwardhan GA; Zhang QJ; Yin D; Gupta V; Bao J; Senkal CE; Ogretmen B; Cabot MC; Shah GV; Sylvester PW; Jazwinski SM; Liu YY
PLoS One; 2009 Sep; 4(9):e6938. PubMed ID: 19742320
[TBL] [Abstract][Full Text] [Related]
2. Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling.
Liu YY; Gupta V; Patwardhan GA; Bhinge K; Zhao Y; Bao J; Mehendale H; Cabot MC; Li YT; Jazwinski SM
Mol Cancer; 2010 Jun; 9():145. PubMed ID: 20540746
[TBL] [Abstract][Full Text] [Related]
3. Mixed backbone antisense glucosylceramide synthase oligonucleotide (MBO-asGCS) loaded solid lipid nanoparticles: in vitro characterization and reversal of multidrug resistance in NCI/ADR-RES cells.
Siddiqui A; Patwardhan GA; Liu YY; Nazzal S
Int J Pharm; 2010 Nov; 400(1-2):251-9. PubMed ID: 20816930
[TBL] [Abstract][Full Text] [Related]
4. Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells.
Liu YY; Han TY; Yu JY; Bitterman A; Le A; Giuliano AE; Cabot MC
J Lipid Res; 2004 May; 45(5):933-40. PubMed ID: 14967819
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin and MBO-asGCS oligonucleotide loaded lipid nanoparticles overcome multidrug resistance in adriamycin resistant ovarian cancer cells (NCI/ADR-RES).
Siddiqui A; Gupta V; Liu YY; Nazzal S
Int J Pharm; 2012 Jul; 431(1-2):222-9. PubMed ID: 22562053
[TBL] [Abstract][Full Text] [Related]
6. Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance.
Liu YY; Han TY; Giuliano AE; Hansen N; Cabot MC
J Biol Chem; 2000 Mar; 275(10):7138-43. PubMed ID: 10702281
[TBL] [Abstract][Full Text] [Related]
7. Ceramide reduction and transcriptional up-regulation of glucosylceramide synthase through doxorubicin-activated Sp1 in drug-resistant HL-60/ADR cells.
Uchida Y; Itoh M; Taguchi Y; Yamaoka S; Umehara H; Ichikawa S; Hirabayashi Y; Holleran WM; Okazaki T
Cancer Res; 2004 Sep; 64(17):6271-9. PubMed ID: 15342415
[TBL] [Abstract][Full Text] [Related]
8. A role for ceramide in driving cancer cell resistance to doxorubicin.
Liu YY; Yu JY; Yin D; Patwardhan GA; Gupta V; Hirabayashi Y; Holleran WM; Giuliano AE; Jazwinski SM; Gouaze-Andersson V; Consoli DP; Cabot MC
FASEB J; 2008 Jul; 22(7):2541-51. PubMed ID: 18245173
[TBL] [Abstract][Full Text] [Related]
9. Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs.
Gouazé V; Liu YY; Prickett CS; Yu JY; Giuliano AE; Cabot MC
Cancer Res; 2005 May; 65(9):3861-7. PubMed ID: 15867385
[TBL] [Abstract][Full Text] [Related]
10. Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells.
Liu YY; Patwardhan GA; Bhinge K; Gupta V; Gu X; Jazwinski SM
Cancer Res; 2011 Mar; 71(6):2276-85. PubMed ID: 21278235
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Glucosylceramide Synthase Sensitizes Head and Neck Cancer to Cisplatin.
Roh JL; Kim EH; Park JY; Kim JW
Mol Cancer Ther; 2015 Aug; 14(8):1907-15. PubMed ID: 26063766
[TBL] [Abstract][Full Text] [Related]
12. The absence of functional glucosylceramide synthase does not sensitize melanoma cells for anticancer drugs.
Veldman RJ; Mita A; Cuvillier O; Garcia V; Klappe K; Medin JA; Campbell JD; Carpentier S; Kok JW; Levade T
FASEB J; 2003 Jun; 17(9):1144-6. PubMed ID: 12692077
[TBL] [Abstract][Full Text] [Related]
13. Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma.
Stefanovic M; Tutusaus A; Martinez-Nieto GA; Bárcena C; de Gregorio E; Moutinho C; Barbero-Camps E; Villanueva A; Colell A; Marí M; García-Ruiz C; Fernandez-Checa JC; Morales A
Oncotarget; 2016 Feb; 7(7):8253-67. PubMed ID: 26811497
[TBL] [Abstract][Full Text] [Related]
14. Ceramide glycosylation potentiates cellular multidrug resistance.
Liu YY; Han TY; Giuliano AE; Cabot MC
FASEB J; 2001 Mar; 15(3):719-30. PubMed ID: 11259390
[TBL] [Abstract][Full Text] [Related]
15. 3-Ketone-4,6-diene ceramide analogs exclusively induce apoptosis in chemo-resistant cancer cells.
Ponnapakam AP; Liu J; Bhinge KN; Drew BA; Wang TL; Antoon JW; Nguyen TT; Dupart PS; Wang Y; Zhao M; Liu YY; Foroozesh M; Beckman BS
Bioorg Med Chem; 2014 Feb; 22(4):1412-20. PubMed ID: 24457089
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of glucosylceramide synthase in associated with multidrug resistance of leukemia cells.
Xie P; Shen YF; Shi YP; Ge SM; Gu ZH; Wang J; Mu HJ; Zhang B; Qiao WZ; Xie KM
Leuk Res; 2008 Mar; 32(3):475-80. PubMed ID: 17709137
[TBL] [Abstract][Full Text] [Related]
17. Direct quantitative determination of ceramide glycosylation in vivo: a new approach to evaluate cellular enzyme activity of glucosylceramide synthase.
Gupta V; Patwardhan GA; Zhang QJ; Cabot MC; Jazwinski SM; Liu YY
J Lipid Res; 2010 Apr; 51(4):866-74. PubMed ID: 19826105
[TBL] [Abstract][Full Text] [Related]
18. MDR1 (multidrug resistence 1) can regulate GCS (glucosylceramide synthase) in breast cancer cells.
Zhang X; Wu X; Li J; Sun Y; Gao P; Zhang C; Zhang H; Zhou G
J Surg Oncol; 2011 Oct; 104(5):466-71. PubMed ID: 21538359
[TBL] [Abstract][Full Text] [Related]
19. Targeting glucosylceramide synthase downregulates expression of the multidrug resistance gene MDR1 and sensitizes breast carcinoma cells to anticancer drugs.
Sun Y; Zhang T; Gao P; Meng B; Gao Y; Wang X; Zhang J; Wang H; Wu X; Zheng W; Zhou G
Breast Cancer Res Treat; 2010 Jun; 121(3):591-9. PubMed ID: 19693666
[TBL] [Abstract][Full Text] [Related]
20. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells.
Liu YY; Han TY; Giuliano AE; Cabot MC
J Biol Chem; 1999 Jan; 274(2):1140-6. PubMed ID: 9873062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]